# A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

Study · id `cardio:ct-nct06647745` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06647745](<https://clinicaltrials.gov/study/NCT06647745>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06647745

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.

## Technical summary

Registry record NCT06647745. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-10 (actual); primary completion 2026-11-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 222 participants (enrolled count; ClinicalTrials.gov record NCT06647745, source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)
- Started: 2025-04-10 (actual) (ClinicalTrials.gov record NCT06647745, source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2026-11-04 (actual) (ClinicalTrials.gov record NCT06647745, source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)
- Completion: 2027-01-28 (anticipated) (ClinicalTrials.gov record NCT06647745, source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)
- Countries: South Korea; Thailand (ClinicalTrials.gov record NCT06647745, source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06647745-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
- Acronym: THP-001-031
- Condition: Type 2 Diabetes
- Condition: Hypertension
- Intervention (Drug): THP-00101
- Intervention (Drug): THP-00102
- Intervention (Drug): THP-00103
- Intervention (Drug): THP-00104
- Intervention (Drug): THP-00105
- Intervention (Drug): THP-00106
- Lead sponsor: THPharm Corp.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 8af0ff5fde0caba932f90518d88582aa03d0ae5236796c2d368b02fb1397d0f6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
